Any current/future capex/capital investment/strategic investment?

The R&D capex for the new R&D center in Panchkula, Haryana, is already committed with an expenditure of Rs 10-15 crores expected this year. The Jammu facility's major capex is mostly completed with about Rs 450 crores invested so far. Future capex, apart from maintenance, will only be undertaken when planning for a new manufacturing facility; currently, maintenance capex is estimated at 3-4% of the gross block. The Jammu greenfield expansion is progressing as planned, expected to commercialize in Q2 FY25, with revenue starting from Q3 FY25. Jammu unit will have four independent manufacturing b

Future growth expectations in sales/revenue/volumes?

The company expects to maintain a strong growth trajectory, aiming to double revenue and bottom-line over the next 3-4 years, driven primarily by the new Jammu facility. Jammu plant is projected to generate Rs 800-900 crores of sales in 3-4 years, with revenue start anticipated from Q3 FY25. The Jammu facility is expected to deliver better-than-Rs 200-300 crores revenue in FY25. Regular business (excluding Jammu) is expected to grow in the early teens percentage range due to capacity constraints. Overall blended growth for the current year is estimated between 12%-15%, with margins expected to

Future growth expectations in earnings/operating earnings/profits/EPS?

Innova Captab Limited aims to double its revenue and bottom-line numbers in the next 3 years, aided by the new Jammu plant commissioning in Q2 FY25. Jammu facility is expected to generate Rs 800-900 crores in sales over 3-4 years, contributing significantly to growth. Revenue from Jammu might start from Q3 FY25 with margin improvement becoming noticeable from the second year onwards. Regular business excluding Jammu anticipates early teens percentage growth due to capacity constraints, with most volume growth coming from Jammu. Overall business expects blended growth around 12%-15% for

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly state the current or expected order book or pending orders for Innova Captab Limited. However, the company expects strong growth from the Jammu facility, aiming for Rs 800-900 crores in revenues over the next 3-4 years. The Jammu plant is anticipated to start commercial operations by Q2 FY25, with revenues kicking in from Q3 FY25. Domestic CDMO business inquiries are increasing, partly driven by regulatory changes like Schedule M compliance leading to industry consolidation. The company services over 190 clients including top pharma companies, reflecting a he

Innova CaptabQ1 FY25Pharmaceuticals & Biotechnology

Innova Captab Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,168P/E: 47.6Market Cap: ₹7.3K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

The company expects to maintain a strong growth trajectory, aiming to double revenue and bottom-line over the next 3-4 years, driven primarily by the new Jammu facility.
Jammu plant is projected to generate Rs 800-900 crores of sales in 3-4 years, with revenue start anticipated from Q3 FY25.
The Jammu facility is expected to deliver better-than-Rs 200-300 crores revenue in FY25.
Regular business (excluding Jammu) is expected to grow in the early teens percentage range due to capacity constraints.
Overall blended growth for the current year is estimated between 12%-15%, with margins expected to remain at similar levels.
Trade generics business aims to double within 3 years, maintaining its current ~17% share.
Expansion of product categories and R&D investment supports long-term volume and revenue growth.

Margin guidance

Category 3

Innova Captab Limited aims to double its revenue and bottom-line numbers in the next 3 years, aided by the new Jammu plant commissioning in Q2 FY25.
Jammu facility is expected to generate Rs 800-900 crores in sales over 3-4 years, contributing significantly to growth.
Revenue from Jammu might start from Q3 FY25 with margin improvement becoming noticeable from the second year onwards.
Regular business excluding Jammu anticipates early teens percentage growth due to capacity constraints, with most volume growth coming from Jammu.
Overall business expects blended growth around 12%-15% for the current year and potential margin stability around 15%.
The company targets sustainable long-term growth through capacity expansion, new R&D center in Panchkula, and increased geographical and product reach.
EBITDA margins remain steady historically in the 14%-16% range.
Focus on value-added products and compliance with regulatory standards to capture increased CDMO demand post Schedule M enhancements.

See what Innova Captab management said on margin guidance — free account, 30 seconds.

Fundraise plans

The provided transcript does not explicitly mention any current or future plans for fundraising through debt or equity by Innova Captab Limited. Key points related to financial plans include: - Capex guidance focuses primarily on the new R&D plant in Panchkula with Rs 10-15 crores expenditure this year. - Jammu facility capex is mostly completed; future capex limited to 3-4% maintenance until new manufacturing facilities are planned. - No explicit mention of plans for raising funds via debt or equity. - Company expects to fund growth from existing operations and capital investments without indicating external fundraising. Therefore, as per the available information, there is no indication of current or upcoming fundraising through debt or equity.

Order book

The transcript does not explicitly state the current or expected order book or pending orders for Innova Captab Limited.
However, the company expects strong growth from the Jammu facility, aiming for Rs 800-900 crores in revenues over the next 3-4 years.
The Jammu plant is anticipated to start commercial operations by Q2 FY25, with revenues kicking in from Q3 FY25.
Domestic CDMO business inquiries are increasing, partly driven by regulatory changes like Schedule M compliance leading to industry consolidation.
The company services over 190 clients including top pharma companies, reflecting a healthy demand pipeline.
With expansion and product development initiatives (new R&D center and Jammu facility), they foresee sustained growth and an increase in order inflows going forward.

See what Innova Captab management said on order book — free account, 30 seconds.

Capex plans

Yes

The R&D capex for the new R&D center in Panchkula, Haryana, is already committed with an expenditure of Rs 10-15 crores expected this year.
The Jammu facility's major capex is mostly completed with about Rs 450 crores invested so far.
Future capex, apart from maintenance, will only be undertaken when planning for a new manufacturing facility; currently, maintenance capex is estimated at 3-4% of the gross block.
The Jammu greenfield expansion is progressing as planned, expected to commercialize in Q2 FY25, with revenue starting from Q3 FY25.
Jammu unit will have four independent manufacturing blocks, enhancing the product portfolio and capacity.
Long-term, the Jammu plant has asset potential to generate up to Rs 2,000 crores in topline at 40-50% utilization, targeting Rs 800-900 crores in 3-4 years.
No additional major capex is planned until the next facility is announced.

Track Innova Captab — get its next earnings analysis in your feed

How does Innova Captab rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisInnova Captab

Rev 2Mar 3

See where Innova Captab sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Innova Captab rank in Pharmaceuticals & Biotechnology?

Compare Innova Captab against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Innova Captab's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →